- ►diabetesjournals.org PE Cryer, SN Davis, H Shamoon - Diabetes Care, 2003 - Am Diabetes Assoc Iatrogenic hypoglycemia causes recurrent morbidity in most people with type 1
diabetes and many with type 2 diabetes, and it is sometimes fatal. The barrier
of hypoglycemia generally precludes maintenance of euglycemia over a ... Cited by 370 - Related articles - All 8 versions
P Cryer - Diabetologia, 2002 - Springer Hypoglycaemia is the limiting factor in the glycaemic management of diabetes.
Iatrogenic hypoglycaemia is typically the result of the interplay of insulin
excess and compromised glucose counterregulation in Type I ... Cited by 221 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org M Davies, F Storms, S Shutler, M Bianchi- … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—At baseline, mean diabetes duration was 12.3 ± 7.2 years, and 72% of
subjects were pretreated with insulin. At end point, there was no significant
difference in the incidence of severe hypoglycemia between algorithms 1 and ... Cited by 65 - Related articles - All 10 versions
HE Scholtz, SG Pretorius, DH Wessels, RHA … - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: This single-dose, double- blind, randomised,
parallel-group study evaluated the reproducibility in systemic exposure and
glucodynamic effect of insulin glargine, NPH insulin (NPH) and insulin ... Cited by 61 - Related articles - BL Direct - All 3 versions
SS Braithwaite, MM Buie, CL Thompson, DF … - Endocrine Practice, 2004 - AACE At the time of completion of the Diabetes Control and Complications Trial
(DCCT), Cryer et al (1-3) observed that, among patients having type 1 diabetes,
iatrogenic hypoglycemia was the principal barrier that prevented attainment ... Cited by 46 - Related articles - BL Direct - All 2 versions
SA Amiel, T Dixon, R Mann, K Jameson - Diabetic Medicine, 2008 - pubmedcentral.nih.gov The primary cause of hypoglycaemia in Type 2 diabetes is diabetes
medication—in particular, those which raise insulin levels independently of
blood glucose, such as sulphonylureas (SUs) and exogenous insulin. The risk ... Cited by 28 - Related articles - BL Direct - All 7 versions
JH DeVries, M Nattrass, TR Pieber - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 21 - Related articles - BL Direct - All 2 versions
- ►shouxi.net VJ Briscoe, SN Davis - Clinical Diabetes, 2006 - Am Diabetes Assoc Donnelly et al. 13 randomly surveyed individuals (n = 267) with type 1 diabetes
and insulin-treated type 2 diabetes to prospectively record hypoglycemic events
encountered over a 4-week period. Of the 267 subjects, 155 reported 572 ... Cited by 19 - Related articles - BL Direct - All 6 versions
D Cobden, WC Lee, S Balu, AV Joshi, CL … - Pharmacotherapy, 2007 - PPI David Cobden, MPH, MS, Won Chan Lee, Ph.D., Sanjeev Balu, Ph.D., Ashish V.
Joshi, Ph.D., and Chris L. Pashos, Ph.D. ... Study Objective. To evaluate
claims-related treatment adherence, health care resource utilization, and ... Cited by 9 - Related articles - BL Direct - All 3 versions
V Fleishman, RS Nocon, SA Spurgeon - Diabetes Technology & Therapeutics, 2005 - liebertonline.com T HE N EW E NGLAND H EALTHCARE I NSTITUTE (NEHI), a non-profit health research
and policy organization, recently analyzed the po- tential impact of an evolving
class of technol- ogy—continuous glucose monitoring (CGM). (The ... Cited by 3 - Related articles - All 4 versions
